New contrast agent shows promise for brain tumor MRI scans

NCT ID NCT06057168

Completed Diagnosis Sponsor: Guerbet Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 3 trial tested whether Elucirem (gadopiclenol) provides better MRI images of brain gliomas compared to the standard contrast agent Dotarem. 138 adults with primary or recurrent brain tumors received one of the two agents during DSC-MRI perfusion scans. The main goal was to compare the quality of blood flow maps, rated as poor, fair, good, or excellent by independent readers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elucirem (gadopiclenol)
What this could lead to: If successful, Elucirem could become a better contrast agent for MRI scans of brain tumors, helping doctors see tumor blood flow more clearly.
What could go wrong: This is a completed Phase 3 trial, but it only compares image quality, not patient outcomes. The new agent may not be significantly better than the current standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain glioma brain neoplasm primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR RECURRENT BRAIN TUMOR, PRIMARY

Contacts and locations

Locations

Debreceni Egyetem

Debrecen, Hungary
IRCCS C.Mondino, Istituto Neurologico Nazionale, Fondazione

Pavia, Italy
Independent Public Teaching Hospital no 1 Department of Interventional Radiology and Diagnostic Imaging

Lublin, Poland
Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá

Budapest, Hungary
Ospedale Papa Giovanni XXIII

Bergamo, Italy
Ospedale San Raffaele- Neuroradiologia

Milan, Italy
Pecsi Tudomanyegyetem Klinikai Kozpont

Pécs, Hungary
Policlinico Universitario Agostino Gemelli

Roma, Italy
Semmelweis Egyetem - Neurologiai Klinika

Budapest, Hungary
Szpital Specjalistyczny im.L.Rydygiera

Krakow, Poland
Uniwersyteckie Centrum Kliniczne w Gdansku

Gdansk, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.